Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial-Reference-Cited by-同舟云学术

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Published:2021-03 Issue:3 Volume:16 Page:452-463
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nishio Makoto,Yoshida Tatsuya,Kumagai Toru,Hida Toyoaki,Toyozawa Ryo,Shimokawaji Tadasuke,Goto Koichi,Nakagawa Kazuhiko,Ohe Yuichiro,Seto Takashi,Kudou Kentarou,Asato Takayuki,Zhang Pingkuan,Yamamoto Nobuyuki

Funder

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic InterGroup (IFCT);Barlesi;Lancet,2016

2. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

3. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer;Gainor;Clin Cancer Res,2013

4. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC);Golding;Mol Cancer,2018

5. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial;Hida;Lancet,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study;ESMO Open;2024-08

2. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08

3. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29

4. Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-01-30

5. Hirnmetastasen;Pneumologie;2024-01-24